127 related articles for article (PubMed ID: 23289686)
1. Beyond human subjects: risk, ethics, and clinical development of nanomedicines.
Kimmelman J
J Law Med Ethics; 2012; 40(4):841-7. PubMed ID: 23289686
[TBL] [Abstract][Full Text] [Related]
2. Responsible conduct in nanomedicine research: environmental concerns beyond the common rule.
Resnik DB
J Law Med Ethics; 2012; 40(4):848-55. PubMed ID: 23289687
[TBL] [Abstract][Full Text] [Related]
3. Prudent precaution in clinical trials of nanomedicines.
Marchant GE; Lindor RA
J Law Med Ethics; 2012; 40(4):831-40. PubMed ID: 23289685
[TBL] [Abstract][Full Text] [Related]
4. Building an ethical foundation for first-in-human nanotrials.
Dresser R
J Law Med Ethics; 2012; 40(4):802-8. PubMed ID: 23289682
[TBL] [Abstract][Full Text] [Related]
5. Handling worker and third-party exposures to nanotherapeutics during clinical trials.
Ramachandran G; Howard J; Maynard A; Philbert M
J Law Med Ethics; 2012; 40(4):856-64. PubMed ID: 23289688
[TBL] [Abstract][Full Text] [Related]
6. Concepts of risk in nanomedicine research.
Hogle LF
J Law Med Ethics; 2012; 40(4):809-22. PubMed ID: 23289683
[TBL] [Abstract][Full Text] [Related]
7. A portrait of nanomedicine and its bioethical implications.
Hall RM; Sun T; Ferrari M
J Law Med Ethics; 2012; 40(4):763-79. PubMed ID: 23289679
[TBL] [Abstract][Full Text] [Related]
8. What is unique about nanomedicine? The significance of the mesoscale.
Khushf G; Siegel RA
J Law Med Ethics; 2012; 40(4):780-94. PubMed ID: 23289680
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine first-in-human research: challenges for informed consent.
King NM
J Law Med Ethics; 2012; 40(4):823-30. PubMed ID: 23289684
[TBL] [Abstract][Full Text] [Related]
10. Translating stem cell research: challenges at the research frontier.
Magnus D
J Law Med Ethics; 2010; 38(2):267-76. PubMed ID: 20579250
[TBL] [Abstract][Full Text] [Related]
11. Introduction: the challenge of nanomedicine human subjects research: protecting participants, workers, bystanders, and the environment.
Wolf SM
J Law Med Ethics; 2012; 40(4):712-5. PubMed ID: 23289676
[No Abstract] [Full Text] [Related]
12. Ethical issues in clinical trials involving nanomedicine.
Resnik DB; Tinkle SS
Contemp Clin Trials; 2007 Jul; 28(4):433-41. PubMed ID: 17166777
[TBL] [Abstract][Full Text] [Related]
13. Ethics. Human health research ethics.
Silbergeld E; Lerman S; Hushka L
Science; 2004 Aug; 305(5686):949. PubMed ID: 15310879
[No Abstract] [Full Text] [Related]
14. Ethics in nanomedicine.
Resnik DB; Tinkle SS
Nanomedicine (Lond); 2007 Jun; 2(3):345-50. PubMed ID: 17716179
[TBL] [Abstract][Full Text] [Related]
15. Ethical issues in nanomedicine: Tempest in a teapot?
Allon I; Ben-Yehudah A; Dekel R; Solbakk JH; Weltring KM; Siegal G
Med Health Care Philos; 2017 Mar; 20(1):3-11. PubMed ID: 27522374
[TBL] [Abstract][Full Text] [Related]
16. Time for new rules on human subjects research?
Dresser R
Hastings Cent Rep; 1998; 28(6):23-4. PubMed ID: 9868606
[No Abstract] [Full Text] [Related]
17. Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field.
Fatehi L; Wolf SM; McCullough J; Hall R; Lawrenz F; Kahn JP; Jones C; Campbell SA; Dresser RS; Erdman AG; Haynes CL; Hoerr RA; Hogle LF; Keane MA; Khushf G; King NM; Kokkoli E; Marchant G; Maynard AD; Philbert M; Ramachandran G; Siegel RA; Wickline S
J Law Med Ethics; 2012; 40(4):716-50. PubMed ID: 23289677
[TBL] [Abstract][Full Text] [Related]
18. Ethicist faults human research subject protection.
Marwick C
JAMA; 1994 Apr; 271(16):1228-9. PubMed ID: 8151885
[No Abstract] [Full Text] [Related]
19. Assessing benefits in clinical research: why diversity in benefit assessment can be risky.
Churchill LR; Nelson DK; Henderson GE; King NM; Davis AM; Leahey E; Wilfond BS
IRB; 2003; 25(3):1-8. PubMed ID: 14569987
[No Abstract] [Full Text] [Related]
20. Upstream ethics in nanomedicine: a call for research.
Khushf G
Nanomedicine (Lond); 2007 Aug; 2(4):511-21. PubMed ID: 17716134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
